checkAd
    Startseite > Aktien > TME Pharma > Nachrichten
    TME Pharma Aktie
    0,2453
     
    EUR
    -2,49 %
    -0,0063 EUR
    Letzter Kurs 12:00:21 Lang & Schwarz
    0,2435
     
    EUR
    3.347 STK
    Geldkurs 12:00:21
    0,2470
     
    EUR
    3.347 STK
    Briefkurs 12:00:21
    ISIN: NL0015000YE1 · WKN: A3DMC3 · Niederlande

    Neueste Nachrichten

    TME Pharma Publishes 2023 Financial Results and Provides Operating Update
    25.04.24 · Business Wire (engl.) · TME Pharma
    TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two‑Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer
    23.04.24 · Business Wire (engl.) · TME Pharma
    TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer
    02.04.24 · Business Wire (engl.) · TME Pharma
    TME Pharma Provides Results of First Exercise of Warrants Z
    28.03.24 · Business Wire (engl.) · TME Pharma
    TME Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for NOX-A12 Phase 2 Trial in Brain Cancer
    05.03.24 · Business Wire (engl.) · TME Pharma
    TME Pharma Provides Results of Final Exercise of Warrants Y: Additional €854K Raised and Extension of Cash Runway From May Into July 2024
    23.02.24 · Business Wire (engl.) · TME Pharma
    TME Pharma Announces the End of the Convertible Debt Program With the Successful €1.48 Million Financing Intended for Buyback of All Outstanding Convertible Debt
    09.02.24 · Business Wire (engl.) · TME Pharma
    TME Pharma Announces Final Median Overall Survival Data Reaching 19.9 Months for NOX-A12 Combination Regimen in GLORIA Brain Cancer Trial and Survival Rate 10-Fold Greater Than Standard of Care
    02.02.24 · Business Wire (engl.) · TME Pharma
    TME Pharma N.V.: Half-yearly Report on the Liquidity Contract With Invest Securities
    31.01.24 · Business Wire (engl.) · TME Pharma
    TME Pharma Provides Update on Number of Outstanding Shares and Warrants Following First Warrant Y Exercise Period
    23.01.24 · Business Wire (engl.) · TME Pharma
    TME Pharma Announces Successful Advice Meeting With US Food and Drug Administration on NOX-A12 Development in Brain Cancer
    09.01.24 · Business Wire (engl.) · TME Pharma
    TME Pharma Announces Further Improvement in Median Overall Survival at 19 Months Follow-up in GLORIA Brain Cancer Trial
    20.12.23 · Business Wire (engl.) · TME Pharma